136 related articles for article (PubMed ID: 32743471)
1. Editorial Comment to Primary basal cell carcinoma of the prostate with concurrent adenocarcinoma.
Funahashi Y
IJU Case Rep; 2020 Mar; 3(2):61. PubMed ID: 32743471
[No Abstract] [Full Text] [Related]
2. Primary basal cell carcinoma of the prostate with concurrent adenocarcinoma.
Hennes D; Dragovic A; Sewell J; Hoh MY; Grills R
IJU Case Rep; 2020 Mar; 3(2):57-60. PubMed ID: 32743470
[TBL] [Abstract][Full Text] [Related]
3. Editorial Comment to Prostate squamous cell carcinoma developing 11 years after external radiotherapy for prostate adenocarcinoma.
Uehara S
IJU Case Rep; 2020 Jul; 3(4):124. PubMed ID: 33392468
[No Abstract] [Full Text] [Related]
4. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin.
Williamson SR; Zhang S; Yao JL; Huang J; Lopez-Beltran A; Shen S; Osunkoya AO; MacLennan GT; Montironi R; Cheng L
Mod Pathol; 2011 Aug; 24(8):1120-7. PubMed ID: 21499238
[TBL] [Abstract][Full Text] [Related]
5. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.
Hansel DE; Nakayama M; Luo J; Abukhdeir AM; Park BH; Bieberich CJ; Hicks JL; Eisenberger M; Nelson WG; Mostwin JL; De Marzo AM
Prostate; 2009 May; 69(6):603-9. PubMed ID: 19125417
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Survival After Definitive Concurrent Chemoradiation Therapy for Synchronous Small Cell Neuroendocrine Carcinoma of the Urinary Bladder and Adenocarcinoma of the Prostate: A Case Report.
Hsieh MT; Tustin R; Le T; Mohd Tahir AR; Shakespeare TP
Cureus; 2024 Jan; 16(1):e51481. PubMed ID: 38298282
[TBL] [Abstract][Full Text] [Related]
7. Sarcomatoid carcinoma of the prostate: a study of 42 cases.
Hansel DE; Epstein JI
Am J Surg Pathol; 2006 Oct; 30(10):1316-21. PubMed ID: 17001164
[TBL] [Abstract][Full Text] [Related]
8. Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate.
Zhao J; Xu N; Zhu S; Nie L; Zhang M; Zheng L; Cai D; Sun X; Chen J; Dai J; Ni Y; Wang Z; Zhang X; Liang J; Chen Y; Hu X; Pan X; Yin X; Liu H; Zhao F; Zhang B; Chen H; Miao J; Qin C; Zhao X; Yao J; Liu Z; Liao B; Wei Q; Li X; Liu J; Gao AC; Huang H; Shen P; Chen N; Zeng H; Sun G
Cancer Res; 2024 Jan; 84(1):154-167. PubMed ID: 37847513
[TBL] [Abstract][Full Text] [Related]
9. Synchronous Penile Squamous Cell Carcinoma, Bladder Urothelial Carcinoma and Prostate Adenocarcinoma Diagnosed in One Procedure.
Deng F; Kong MX; Lai J
Anticancer Res; 2022 Jul; 42(7):3601-3605. PubMed ID: 35790255
[TBL] [Abstract][Full Text] [Related]
10. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
[TBL] [Abstract][Full Text] [Related]
11. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
[TBL] [Abstract][Full Text] [Related]
12. Adenoid cystic/basal cell carcinoma of the prostate: review and update.
Begnami MD; Quezado M; Pinto P; Linehan WM; Merino M
Arch Pathol Lab Med; 2007 Apr; 131(4):637-40. PubMed ID: 17425398
[TBL] [Abstract][Full Text] [Related]
13. Prostate basal cell lesions can be negative for basal cell keratins: a diagnostic pitfall.
Zhou M; Magi-Galluzzi C; Epstein JI
Anal Quant Cytol Histol; 2006 Jun; 28(3):125-9. PubMed ID: 16786721
[TBL] [Abstract][Full Text] [Related]
14. Reliability of the 34βE12, keratin 5/6, p63, bcl-2, and AMACR in the diagnosis of prostate carcinoma.
Boran C; Kandirali E; Yilmaz F; Serin E; Akyol M
Urol Oncol; 2011; 29(6):614-23. PubMed ID: 20189848
[TBL] [Abstract][Full Text] [Related]
15.
Makabe S; Koguchi T; Matsuoka K; Hoshi S; Hata J; Sato Y; Akaihata H; Kataoka M; Uemura M; Kojima Y
IJU Case Rep; 2023 Jul; 6(4):248-252. PubMed ID: 37405037
[TBL] [Abstract][Full Text] [Related]
16. ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63.
Torres A; Alshalalfa M; Davicioni E; Gupta A; Yegnasubramanian S; Wheelan SJ; Epstein JI; De Marzo AM; Lotan TL
Prostate; 2018 Sep; 78(12):896-904. PubMed ID: 29761525
[TBL] [Abstract][Full Text] [Related]
17. Basal Cell Carcinoma of Prostate With MSMB-NCOA4 Fusion and a Probable Basal Cell Carcinoma In Situ: Case Report.
Pedersen V; Petersen KS; Brasso K; Østrup O; Loya AC
Int J Surg Pathol; 2021 Dec; 29(8):850-855. PubMed ID: 33978524
[TBL] [Abstract][Full Text] [Related]
18. Atypical basal cell hyperplasia of the prostate.
Epstein JI; Armas OA
Am J Surg Pathol; 1992 Dec; 16(12):1205-14. PubMed ID: 1281386
[TBL] [Abstract][Full Text] [Related]
19. Re: Editorial comment on clinicopathological characteristics of prostatic adenocarcinoma in men with atypical prostate needle biopsies.
Iczkowski KA
J Urol; 1999 Jan; 161(1):231. PubMed ID: 10037410
[No Abstract] [Full Text] [Related]
20. Intraductal Adenocarcinoma of the Prostate With Cribriform or Papillary Ductal Morphology: Rare Biopsy Cases Lacking Associated Invasive High-grade Carcinoma.
Russell DH; Epstein JI
Am J Surg Pathol; 2022 Feb; 46(2):233-240. PubMed ID: 34619708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
